Literature DB >> 10172705

Treating myocardial infarction in the post-GUSTO era. A US perspective.

D B Mark1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1996        PMID： 10172705     DOI： 10.2165/00019053-199609060-00001

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN： 1170-7690            Impact factor:   4.981


× No keyword cloud information.
  20 in total

1.  One-year outcome after therapy with tissue plasminogen activator: report from the Thrombolysis and Angioplasty in Myocardial Infarction trial.

Authors:  R M Califf; E J Topol; B S George; D J Kereiakes; L G Aronson; K L Lee; L Martin; R Candela; C Abbottsmith; W W O'Neill
Journal:  Am Heart J       Date:  1990-04       Impact factor: 4.749

2.  A randomized trial of intravenous tissue plasminogen activator for acute myocardial infarction with subsequent randomization to elective coronary angioplasty.

Authors:  A D Guerci; G Gerstenblith; J A Brinker; N C Chandra; S O Gottlieb; R D Bahr; J L Weiss; E P Shapiro; J T Flaherty; D E Bush
Journal:  N Engl J Med       Date:  1987-12-24       Impact factor: 91.245

3.  The wavefront phenomenon of ischemic cell death. 1. Myocardial infarct size vs duration of coronary occlusion in dogs.

Authors:  K A Reimer; J E Lowe; M M Rasmussen; R B Jennings
Journal:  Circulation       Date:  1977-11       Impact factor: 29.690

4.  Long-term benefit of early thrombolytic therapy in patients with acute myocardial infarction: 5 year follow-up of a trial conducted by the Interuniversity Cardiology Institute of The Netherlands.

Authors:  M L Simoons; J Vos; J G Tijssen; F Vermeer; F W Verheugt; X H Krauss; V M Cats
Journal:  J Am Coll Cardiol       Date:  1989-12       Impact factor: 24.094

5.  Improved thrombolysis with a modified dose regimen of recombinant tissue-type plasminogen activator.

Authors:  K L Neuhaus; W Feuerer; S Jeep-Tebbe; W Niederer; A Vogt; U Tebbe
Journal:  J Am Coll Cardiol       Date:  1989-11-15       Impact factor: 24.094

6.  A comparison between heparin and low-dose aspirin as adjunctive therapy with tissue plasminogen activator for acute myocardial infarction. Heparin-Aspirin Reperfusion Trial (HART) Investigators.

Authors:  J Hsia; W P Hamilton; N Kleiman; R Roberts; B R Chaitman; A M Ross
Journal:  N Engl J Med       Date:  1990-11-22       Impact factor: 91.245

7.  ISIS-3: a randomised comparison of streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs aspirin alone among 41,299 cases of suspected acute myocardial infarction. ISIS-3 (Third International Study of Infarct Survival) Collaborative Group.

Authors: 
Journal:  Lancet       Date:  1992-03-28       Impact factor: 79.321

8.  Cost effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction.

Authors:  D B Mark; M A Hlatky; R M Califf; C D Naylor; K L Lee; P W Armstrong; G Barbash; H White; M L Simoons; C L Nelson
Journal:  N Engl J Med       Date:  1995-05-25       Impact factor: 91.245

9.  Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction.

Authors:  M A DeWood; J Spores; R Notske; L T Mouser; R Burroughs; M S Golden; H T Lang
Journal:  N Engl J Med       Date:  1980-10-16       Impact factor: 91.245

Review 10.  Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Fibrinolytic Therapy Trialists' (FTT) Collaborative Group.

Authors: 
Journal:  Lancet       Date:  1994-02-05       Impact factor: 79.321
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.